Verapamil Hydrochloride (Verapamil Hydrochloride)

Trade Name : Verapamil Hydrochloride

Hospira, Inc.

INJECTION, SOLUTION

Strength 2.5 mg/mL

Storage and handling for Verapamil Hydrochloride

VERAPAMIL HYDROCHLORIDE P-Glycoprotein Inhibitors [MoA],Calcium Channel Antagonists [MoA],Calcium Channel Blocker [EPC],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA]

Disclaimer

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Verapamil Hydrochloride (Verapamil Hydrochloride) which is also known as Verapamil Hydrochloride and Manufactured by Hospira, Inc.. It is available in strength of 2.5 mg/mL per ml. Read more

Verapamil Hydrochloride (Verapamil Hydrochloride) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials. Click to know price. Read less

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

About GNH

No data

Arrayn- Array
Arrayn- Ampul
Arrayn- Fliptop Vial
Protect from light.
Rx only

Verapamil hydrochloride is a calcium antagonist or slow-channel inhibitor. Verapamil Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing verapamil hydrochloride 2.5 mg/mL and sodium chloride 8.5 mg/mL in water for injection. The solution contains no bacteriostat or antimicrobial agent and is intended for single-dose intravenous administration. May contain hydrochloric acid for pH adjustment; pH is 4.0 to 6.5.
The chemical name of Verapamil Hydrochloride, USP is benzeneacetonitrile, u03b1-[3-[{2-(3,4-dimethoxyphenyl)ethyl} methylamino] propyl]-3,4-dimethoxy-u03b1-(1-methylethyl) hydrochloride. Verapamil hydrochloride is a white or practically white crystalline powder. It is practically odorless and has a bitter taste. It is soluble in water; freely soluble in chloroform; sparingly soluble in alcohol; practically insoluble in ether. It has the following structural formula:
Molecular weight: 491.07
Molecular formula: CHNOu2022 HCl
Verapamil hydrochloride is not chemically related to other antiarrhythmic drugs.
The plastic syringe is molded from a specially formulated polypropylene. Water permeates from inside the container at an extremely slow rate which will have an insignificant effect on solution concentration over the expected shelf life. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the syringe material.

Arrayn- Mechanism of Action:
In the isolated rabbit heart, concentrations of verapamil that markedly affect SA nodal fibers or fibers in the upper and middle regions of the AV node have very little effect on fibers in the lower AV node (NH region) and no effect on atrial action potentials or His bundle fibers.
Electrical activity in the SA and AV nodes depends, to a large degree, upon calcium influx through the slow channel. By inhibiting this influx, verapamil slows AV conduction and prolongs the effective refractory period within the AV node in a rate-related manner. This effect results in a reduction of the ventricular rate in patients with atrial flutter and/or atrial fibrillation and a rapid ventricular response.
By interrupting reentry at the AV node, verapamil can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardias (PSVT), including PSVT associated with Wolff-Parkinson-White syndrome.
Verapamil does not induce peripheral arterial spasm.
Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis. It is not known whether this action is important at the doses used in man.
Verapamil does not alter total serum calcium levels.
Arrayn- Hemodynamics:
Arrayn- Pharmacokinetics:
Aging may affect the pharmacokinetics of verapamil given to hypertensive patients. Elimination half-life may be prolonged in the elderly.

Verapamil Hydrochloride Injection, USP is indicated for the following:
u2022 Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong-u00a0Levine [L-G-L] syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to verapamil hydrochloride administration.
u2022 Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (Wolff-Parkinson-White (W-P-W) and Lown-Ganong-Levine (L-G-L) syndromes).
In controlled studies in the United States, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil hydrochloride. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a faster ventricular rate respond with a decrease in ventricular rate of at least 20%. Conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after verapamil hydrochloride and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. Slowing of the ventricular rate in patients with atrial fibrillation/flutter lasts 30 to 60 minutes after a single injection.
Arrayn- Because a small fraction (<1%) of patients treated with verapamil hydrochloride respond with life-threatening adverse responses (rapid ventricular rate in atrial flutter/fibrillation, and an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole u2212 see and ), the initial use of verapamil hydrochloride injection should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including D.C.-cardioversion capability (see , Suggested Treatment of Acute Cardiovascular Adverse Reactions). As familiarity with the patient's response is gained, use in an office setting may be acceptable.
Cardioversion has been used safely and effectively after verapamil hydrochloride injection.

Verapamil hydrochloride injection is contraindicated in:
1. Severe hypotension or cardiogenic shock.
2.u00a0Second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker).
3. Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker).
4. Severe congestive heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil therapy).
5. Patients receiving beta-adrenergic blocking drugs (e.g., propranolol). verapamil and beta-adrenergic blocking drugs should not be administered in close proximity to each other (within a few hours), since both may have a depressant effect on myocardial contractility and AV conduction.
6.u00a0u00a0Patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., Wolff- Parkinson-White, Lown-Ganong-Levine syndromes) are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered. Therefore, the use of verapamil in these patients is contraindicated.
7. Ventricular tachycardia: Administration of intravenous verapamil to patients with wide-complex ventricular tachycardia (QRS u2265 0.12 sec) can result in marked hemodynamic deterioration and ventricular fibrillation. Proper pretherapy diagnosis and differentiation from wide-complex supraventricular tachycardia is imperative in the emergency room setting.
8. Known hypersensitivity to verapamil hydrochloride.

Arrayn- VERAPAMIL HYDROCHLORIDE SHOULD BE GIVEN AS A SLOW INTRAVENOUS INJECTION OVER AT LEAST A TWO-MINUTE PERIOD OF TIME (see ).
Arrayn- Hypotension:
Arrayn- Arrayn- Array
Arrayn- Heart Failure:
Arrayn- Concomitant Antiarrhythmic Therapy:
Arrayn- Digitalis:
Arrayn- Procainamide:
Arrayn- Quinidine:
Arrayn- Arrayn- Arrayn- Array
Arrayn- Disopyramide:
Arrayn- Flecainide:
Arrayn- Arrayn- Array
Arrayn- Hepatic and Renal Failure:
Verapamil cannot be removed by hemodialysis.
Arrayn- Premature Ventricular Contractions:
Arrayn- Duchenne's Muscular Dystrophy:
Arrayn- Increased Intracranial Pressure:

No data

The following reactions were reported with verapamil hydrochloride injection used in controlled U.S. clinical trials involving 324 patients:
Arrayn- Cardiovascular:
Arrayn- Central Nervous System Effects:
Arrayn- Gastrointestinal:
In rare cases of hypersensitive patients, broncho/laryngeal spasm accompanied by itch and urticaria has been reported.
The following reactions have been reported at low frequency: emotional depression, rotary nystagmus, sleepiness, vertigo, muscle fatigue, diaphoresis, and respiratory failure.

Treatment of overdosage should be supportive and individualized. Beta-adrenergic stimulation and/or parenteral administration of calcium injections may increase calcium ion flux across the slow channel, and have been effectively used in treatment of deliberate overdosage with oral verapamil hydrochloride. Verapamil cannot be removed by hemodialysis.
Clinically significant hypotensive reactions or high-degree AV block should be treated with vasopressor agents or cardiac pacing, respectively. Asystole should be handled by the usual measures including isoproterenol hydrochloride, other vasopressor agents, or cardiopulmonary resuscitation (see u00a0).

Arrayn- FOR INTRAVENOUS USE ONLY. VERAPAMIL HYDROCHLORIDE INJECTION SHOULD BE GIVEN AS A SLOW INTRAVENOUS INJECTION OVER AT LEAST A TWO-MINUTE PERIOD OF TIME UNDER CONTINUOUS ELECTROCARDIOGRAPHIC (ECG) AND BLOOD PRESSURE MONITORING.
Arrayn- Adult:
Arrayn- Array
Arrayn- Array
Arrayn- Array
Arrayn- Pediatric:
Arrayn- Array
Arrayn- Array
Arrayn- Array
Arrayn- Array
Arrayn- Array
Arrayn- Array
Arrayn- Note:
For stability reasons this product is not recommended for dilution with Sodium Lactate Injection, USP in polyvinyl chloride bags. Verapamil is physically compatible and chemically stable for at least 24 hours at 25u00b0C protected from light in most common large volume parenteral solutions. Admixing verapamil hydrochloride injection with albumin, amphotericin B, hydralazine hydrochloride and trimethoprim with sulfamethoxazole should be avoided. Verapamil hydrochloride injection will precipitate in any solution with a pH above 6.0.

Verapamil Hydrochloride Injection, USP 2.5 mg/mL is supplied in single-dose containers as follows:
Store at 20 to 25u00b0C (68 to 77u00b0F). [See USP Controlled Room Temperature.]
Protect from light by retaining in package until ready to use.
Distributed by Hospira, Inc., Lake Forest, IL 60045 USA
LAB-0885-3.005/2018

ttttttt4 mL Single-dose
NDC 0409-1144-62Rx only
tttttttVerapamil HCl Injection, USP tttttt
ttttttt10 mg/4 mL (2.5 mg/mL) tttttt
Distributed by Hospira, Inc., Lake Forest, IL 60045 USA
Protect from light. For I.V. use only.
RLu20137066

4 mL Single-dose Fliptop Vial
NDC 0409-1144-02Contains 5 of NDC 0409-1144-62
Verapamil Hydrochloride Injection, USP
10 mg/4 mL (2.5 mg/mL)
Protect from light. For Intravenous use only.
Rx only
MADE IN ITALY
Distributed by Hospira, Inc., Lake Forest, IL 60045 USA
Hospira

2 mL Single-dose
NDC 0409-1144-65Rx only
Verapamil HCl Injection, USP 5 mg/2 mL (2.5 mg/mL)
Protect from light. For Intravenous use only.
Dist. by Hospira, Inc., Lake Forest, IL 60045 USA
RLu20137063

25 x 2 mL Single-dose Fliptop Vial
NDC 0409-1144-05Contains 25 of NDC 0409-1144-65
Verapamil Hydrochloride Injection, USP5 mg/2 mL (2.5 mg/mL)
Protect from light.For Intravenous use only.
Rx only
Hospira

2 mL
NDC 0409-4011-61
Verapamil HCl Injection, USP5 mg/2 mL (2.5 mg/mL)
Protect from light.For Intravenous use only.
Rx only
RLu20137064
Distributed by Hospira, Inc.Lake Forest, IL 60045 USA
Hospira

2 mL Single-dose 5 Ampuls
NDC 0409-4011-01Contains 5 of NDC 0409-4011-61
Verapamil Hydrochloride Injection, USP5 mg/2 mL (2.5 mg/mL)
Rx only
Protect from light. Keep ampuls in tray until time of use.For Intravenous use only.
Each mL contains verapamil hydrochloride 2.5 mg (equivalent to t tttttt2.3 mg verapamil); sodium chloride 8.5 mg. May containtttttt tttttthydrochloric acid for pH adjustment. 0.301 mOsmol/mL (calc.)tttttt pH 4.0 to 6.5
Verapamil Hydrochloride Inj., USP should be given as a slow ttttttttttintravenous injection over at least a two minute period of time.tttt ttttttDiscard unused portion. Usual dosage: See insert. Store at 20 tot tttttt25u00b0C (68 to 77u00b0F). [See USP Controlled Room Temperature.]
MADE IN ITALY
Distributed by Hospira, Inc., Lake Forest, IL 60045 USA
Hospira
RL - 6999

Verapamil HCl 10 mg/4 mL (2.5 mg/mL)
4 mL Single-dose syringe
NDC 0409-9633-65
Verapamil HCl Injection, USP10 mg/4 mL (2.5 mg/mL)
Rx only
Protect From Light.
RLu20136823
For Intravenous use only.
Hospira
Distributed by Hospira, Inc.Lake Forest, IL 60045 USA

NDC 0409-9633-65Rx only
4 mL
Verapamil Hydrochloride Injection, USP
10 mg/4 mL (2.5 mg/mL)
Ansyrn
Single-dose Syringe
Protect from light.
For intravenous use only.
Hospira
u25c0 PRESS AND PULL TO OPEN u25b6

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Dossiers and Stability Studies

STABILITY STUDIES STABILITY, BA / BE STUDIES Due to our active

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise